Evaluation of the Serum Levels of IL6 and Magnesium in Chronic Kidney Disease Patients (CKD), and CKD Patients with Different Comorbidities

Background Chronic kidney disease (CKD) is a global health concern that causes a substantial increase in morbidity and mortality rates among adults. CKD is accompanied with several complications including cardiovascular disease (CVD) and death. We aimed to study the relation of level of interleukin-6 (IL-6) in the serum and magnesium (Mg) in CKD and CKD patients with various comorbidities. Methods This cross-sectional study involved 100 CKD adult pre-dialysis patients, they were subdivided into 4 groups; the 1st group included 21 patients with CKD only, the 2nd group included 29 patients with CKD and diabetes mellitus (CKD+DM), the 3rd group included 34 patients with CKD and hypertension (CKD+HTN) and the 4th group included 16 patients with CKD and CVD (CKD+CVD). Results At cutoff value of > 22.4 pg/ml, serum IL-6 with area under the curve (AUC) of 0.957 can significantly predict the progression of the disease (P